John W. Kozarich's most recent trade in Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B was a trade of 159 Common Stock done at an average price of $204.3 . Disclosure was reported to the exchange on April 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 204.26 per share. | 01 Apr 2026 | 159 | 42,253 (0%) | 0% | 204.3 | 32,478 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 199.97 per share. | 01 Apr 2026 | 146 | 42,574 (0%) | 0% | 200.0 | 29,196 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 202.42 per share. | 01 Apr 2026 | 79 | 42,455 (0%) | 0% | 202.4 | 15,991 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 202.91 per share. | 01 Apr 2026 | 43 | 42,412 (0%) | 0% | 202.9 | 8,725 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 201.22 per share. | 01 Apr 2026 | 40 | 42,534 (0%) | 0% | 201.2 | 8,049 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 196.36 per share. | 02 Feb 2026 | 381 | 43,210 (0%) | 0% | 196.4 | 74,814 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 191.00 per share. | 02 Feb 2026 | 39 | 43,615 (0%) | 0% | 191 | 7,449 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 197.17 per share. | 02 Feb 2026 | 23 | 43,187 (0%) | 0% | 197.2 | 4,535 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 195.61 per share. | 02 Feb 2026 | 23 | 43,591 (0%) | 0% | 195.6 | 4,499 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 192.00 per share. | 02 Feb 2026 | 1 | 43,614 (0%) | 0% | 192 | 192 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 190.27 per share. | 02 Jan 2026 | 207 | 43,700 (0%) | 0% | 190.3 | 39,386 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 188.96 per share. | 02 Jan 2026 | 102 | 43,907 (0%) | 0% | 189.0 | 19,274 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 187.96 per share. | 02 Jan 2026 | 91 | 44,009 (0%) | 0% | 188.0 | 17,104 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 192.39 per share. | 02 Jan 2026 | 46 | 43,654 (0%) | 0% | 192.4 | 8,850 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 186.57 per share. | 02 Jan 2026 | 21 | 44,100 (0%) | 0% | 186.6 | 3,918 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 194.76 per share. | 01 Dec 2025 | 179 | 44,317 (0%) | 0% | 194.8 | 34,862 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 193.86 per share. | 01 Dec 2025 | 92 | 44,496 (0%) | 0% | 193.9 | 17,835 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 197.72 per share. | 01 Dec 2025 | 92 | 44,174 (0%) | 0% | 197.7 | 18,190 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 195.81 per share. | 01 Dec 2025 | 47 | 44,270 (0%) | 0% | 195.8 | 9,203 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 200.00 per share. | 01 Dec 2025 | 30 | 44,121 (0%) | 0% | 200 | 6,000 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 199.22 per share. | 01 Dec 2025 | 23 | 44,151 (0%) | 0% | 199.2 | 4,582 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 196.25 per share. | 01 Dec 2025 | 4 | 44,266 (0%) | 0% | 196.3 | 785 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 191.25 per share. | 03 Nov 2025 | 207 | 44,715 (0%) | 0% | 191.3 | 39,589 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 192.38 per share. | 03 Nov 2025 | 127 | 44,588 (0%) | 0% | 192.4 | 24,432 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 189.00 per share. | 03 Nov 2025 | 84 | 44,971 (0%) | 0% | 189 | 15,876 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 190.27 per share. | 03 Nov 2025 | 49 | 44,922 (0%) | 0% | 190.3 | 9,323 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 178.40 per share. | 01 Oct 2025 | 196 | 45,302 (0%) | 0% | 178.4 | 34,967 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 180.01 per share. | 01 Oct 2025 | 155 | 45,147 (0%) | 0% | 180.0 | 27,902 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 181.18 per share. | 01 Oct 2025 | 92 | 45,055 (0%) | 0% | 181.2 | 16,669 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 177.62 per share. | 01 Oct 2025 | 24 | 45,498 (0%) | 0% | 177.6 | 4,263 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 161.51 per share. | 02 Sep 2025 | 267 | 45,722 (0%) | 0% | 161.5 | 43,124 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 162.52 per share. | 02 Sep 2025 | 115 | 45,607 (0%) | 0% | 162.5 | 18,690 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 164.25 per share. | 02 Sep 2025 | 85 | 45,522 (0%) | 0% | 164.2 | 13,961 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 131.88 per share. | 01 Aug 2025 | 467 | 45,989 (0%) | 0% | 131.9 | 61,586 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 125.00 per share. | 10 Jul 2025 | 934 | 46,456 (0%) | 0% | 125 | 116,750 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 5,783 | 5,783 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 1,209 | 47,390 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.30 per share. | 17 Jan 2025 | 2,406 | 46,181 (0%) | 0% | 52.3 | 125,834 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2025 | 2,406 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 5,444 | 5,444 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 1,252 | 43,775 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.35 per share. | 24 Apr 2024 | 2,893 | 42,523 (0%) | 0% | 39.4 | 113,840 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2024 | 2,893 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 5,461 | 5,461 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 1,142 | 39,630 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 77.20 per share. | 16 May 2023 | 4,444 | 38,488 (0%) | 0% | 77.2 | 343,081 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.82 per share. | 08 May 2023 | 6,408 | 48,621 (0%) | 0% | 18.8 | 120,599 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2023 | 6,408 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 76.51 per share. | 08 May 2023 | 5,819 | 42,802 (0%) | 0% | 76.5 | 445,218 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 77.10 per share. | 08 May 2023 | 589 | 42,213 (0%) | 0% | 77.1 | 45,410 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2022 | 6,623 | 6,623 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 4,340 | 4,340 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 1,004 | 42,213 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 7,335 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.53 per share. | 28 Feb 2022 | 7,335 | 42,117 (0%) | 0% | 12.5 | 91,908 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 102.62 per share. | 28 Feb 2022 | 908 | 41,209 (0%) | 0% | 102.6 | 93,179 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 3,269 | 3,269 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 630 | 34,782 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 4,835 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.12 per share. | 11 May 2021 | 4,835 | 34,543 (0%) | 0% | 10.1 | 48,930 | Common Stock |
| Ligand Pharma Inc (Class B) | John W. Kozarich | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 128.56 per share. | 11 May 2021 | 391 | 34,152 (0%) | 0% | 128.6 | 50,267 | Common Stock |